losartan has been researched along with pravastatin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Liebson, PR | 1 |
| Diener, HC | 1 |
| Cha, JH; Kang, DH; Kang, SW; Kim, J; Kim, YS; Li, C; Lim, SW; Song, JC; Sun, BK; Yang, CW | 1 |
| Chang, NC; Lee, TM; Lin, MS; Tsai, CH | 1 |
| Bayraktutan, U; Campbell, M; Mahadevan, VS; McKeown, PP | 1 |
| Herring, N; Lee, CW; Paterson, DJ; Sunderland, N; Wright, K | 1 |
| Black, A; Byrne, J; Dietz, HC; Hill, AD; Huuskonen, V; Kay, E; Kearney, S; McAllister, H; McGuinness, J; McLoughlin, D; Redmond, JM; Terzo, E | 1 |
1 review(s) available for losartan and pravastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for losartan and pravastatin
| Article | Year |
|---|---|
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Drug Interactions; Drug Resistance; Endothelin-1; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Lipids; Losartan; Male; Middle Aged; Pravastatin; Proteinuria; Substance Withdrawal Syndrome | 2005 |
12 other study(ies) available for losartan and pravastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.
Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; Kidney Diseases; Losartan; Male; Pravastatin; Rats; Rats, Sprague-Dawley | 2005 |
Internal mammary artery smooth muscle cells resist migration and possess high antioxidant capacity.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Amides; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Cells, Cultured; Chemotaxis; Coronary Vessels; Enalapril; Farnesyltranstransferase; Free Radical Scavengers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Lipoproteins, LDL; Losartan; Mammary Arteries; Metalloporphyrins; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Pravastatin; Protein Serine-Threonine Kinases; Pyridines; Receptors, Oxidized LDL; rho-Associated Kinases | 2006 |
Pravastatin normalises peripheral cardiac sympathetic hyperactivity in the spontaneously hypertensive rat.
Topics: Animals; Blotting, Western; Cholesterol; Guanylate Cyclase; Heart Rate; Immunohistochemistry; Losartan; Male; NADPH Oxidases; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Peptidyl-Dipeptidase A; Pravastatin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Angiotensin; Tyrosine 3-Monooxygenase | 2011 |
Pravastatin reduces Marfan aortic dilation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Aortic Diseases; Dilatation, Pathologic; Disease Models, Animal; Elastin; Endoplasmic Reticulum; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Marfan Syndrome; Mice; Mice, Mutant Strains; Muscle, Smooth, Vascular; Pravastatin; Treatment Outcome; Tunica Media | 2011 |